FORMYCON AG
Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST
Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!
Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.
Read
Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST
BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!
Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?
Read
Commented by André Will-Laudien on February 14th, 2023 | 15:54 CET
Election winners in the fight against cancer! Bayer, Defence Therapeutics, Formycon, Valneva - 300% rises are possible!
In 2021, 18.7 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. Thanks to growing research successes, however, there is hope that biotechnology will make it much more likely that sufferers will survive. It is a matter of developing suitable active substances or launching modern therapies. Recently, mRNA technology has also been making a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. Which shares are currently in the spotlight?
Read
Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST
Evotec, Defence Therapeutics, Formycon - Biotech opportunity!
Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.
Read
Commented by Stefan Feulner on September 8th, 2022 | 11:02 CEST
SGL Carbon, Viva Gold, Formycon - Strong news in the bear market
The stock markets are reeling, and uncertainties and tensions have increased in recent days. Thus, not only did the stock market corrected, but the DAX sank again significantly below the 13,000 mark due to the stop of gas deliveries via Nord Stream 1, and other asset classes such as precious metals, cryptocurrencies and even oil dropped significantly. Nevertheless, even in the bear market, there are companies that can shine with excellent reports and should be among the winners in a possible upward movement.
Read
Commented by Armin Schulz on September 5th, 2022 | 11:49 CEST
BioNTech, Cardiol Therapeutics, Formycon - Biotech stocks about to make a comeback?
Fears of a recession have recently pushed the markets down again. Those who want to bet on crisis-proof investments should look at biotech stocks. The world population is growing, people are getting older, and in line with age, more diseases are appearing. This trend will continue in the coming years. Therefore, the prospects for success in this sector are excellent. One cannot cut corners on health. Since September 2021, shares of biotech companies have also consolidated strongly. In some cases, shares appear severely undervalued. Today, we look at three interesting companies in the biotech sector.
Read
Commented by André Will-Laudien on July 28th, 2022 | 14:20 CEST
Finding the next BioNTech: MorphoSys, XPhyto Therapeutics, Formycon - Who will make the breakthrough?
The Mainz-based biotech Company BioNTech has shown the way with Cormirnaty®: stringent research and adherence to milestones ultimately lead to success. The main and founding investors Strüngmann are still on board as long-term investors with over 40% even after the price correction. The mRNA technology is now mutating into the basis for a whole new class of drugs, and BioNTech could thus become a new German pharmaceutical giant. The brothers from Tegernsee know what they are talking about. Their start-up capital came from the first major exit after they sold their generic drug manufacturer Hexal, founded in 1979, to Novartis for EUR 5.65 billion in 2005. Since then, they have continued to invest in biotechnology through their family office. The challenge is to find the next BioNTech.
Read
Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST
BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential
A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.
Read
Commented by Stefan Feulner on April 19th, 2022 | 12:10 CEST
Bayer, Defence Therapeutics, Formycon - Biotech stocks facing transformation
The pharmaceutical industry proved to be a key industry in the Corona pandemic, developing tests, vaccines and drugs at record speed and making them available in large quantities. In the process, biotechnology emerged as the innovative engine. The development of new compounds is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs will expire in the future or has already expired. For this reason, the pharmaceutical industry is now entering biotechs much more frequently in the early development phases of a new drug. As a result, early-stage development companies already offer opportunities for multiplication.
Read
Commented by André Will-Laudien on April 4th, 2022 | 12:19 CEST
Bayer, Cardiol Therapeutics, Formycon, NanoRepro: Top Biotech Stocks - Delivering!
Due to various public easing measures, the Corona pandemic is increasingly fading into the background. It has long been a hot ride for the stock market, especially for vaccine producers, but now investors are shifting their focus to other stocks in the biotech segment. After all, there are still many diseases that confront humanity with unresolved mysteries, and the field of human medical research seems endless. We focus on interesting stocks from the sector, which corrected strongly in the wake of the Ukraine downturn but are now trending north again. These trends are still in their infancy.
Read